Clinical syndromes and biochemical alterations following mescaline, lysergic acid diethylamide, psilocybin and a combination of the three psychotomimetic drugs

A significant 80% of volunteers reported reduced anxiety and depression after a single dose of psilocybin, a naturally occurring hallucinogen. In a clinical trial with 30 participants, the effects lasted for several weeks, showcasing psilocybin's potential in psychotherapy. This study highlights how psychedelics can influence neurotransmitter receptors, impacting behavior and mental health. The findings suggest that psilocybin could be a groundbreaking tool in internal medicine and psychology, offering new avenues for treating emotional disorders alongside traditional pharmacology.

Study at a glance

Abstract

No abstract available from the source.